OSAKA - Japanese drugmaker Rohto Pharmaceutical Co. said Thursday it plans to launch a clinical trial using stem cells to develop a treatment for severe cases of COVID-19, the respiratory illness caused by the novel coronavirus.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
